Abstract 2368
Background
Depth of response (DepOR; max % reduction from baseline in sum of target lesion diameters), has shown prognostic value for long-term survival in multiple malignancies. Among aRCC patients (pts) in CheckMate 214, objective response and complete response rates were higher and more durable, and overall survival (OS) was greater (intention-to-treat: HR 0.71, P = 0.0003; intermediate/poor-risk pts: HR 0.66, P < 0.0001), for nivolumab + ipilimumab (N+I) vs sunitinib (S) at 30-mo min follow-up. This exploratory analysis evaluated the relationship between DepOR and OS in CheckMate 214 to determine a potential DepOR threshold predictive of long-term OS with N+I.
Methods
Pts with previously untreated aRCC were randomized 1:1 to N+I (3 mg/kg + 1 mg/kg IV) Q3W for 4 doses, followed by N (3 mg/kg IV) Q2W, or S 50 mg/day orally for 4 wk (6-wk cycles). An exploratory analysis of OS by DepOR quartiles was conducted (Q0, no reduction; Q1, >0–≤25%; Q2, >25–≤50%; Q3, >50–≤75%; Q4, >75–≤100%).
Results
Of 550 and 546 pts randomized to N+I or S, 479 and 459, respectively, had postbaseline target lesion measurements. Overall, greater DepOR was associated with improved OS (Table). Pts on N+I with >50–≤75% (Q3) tumor reduction had similar OS as those with >75% (Q4) reduction, whereas only Q4 pts achieved comparable OS with S (203/550 [37%] N+I vs 46/546 [8%] S randomized pts). Receiver operating characteristic analysis supported a > 50% DepOR threshold for greatest OS benefit with N+I. Additional analyses of the relationship between DepOR and outcomes across arms will be presented.Table:
950P
DepOR | N+I N = 479 | S N = 459 | ||||
---|---|---|---|---|---|---|
n (%) | Median OS, mo (95% CI) | OS probability vs Q0, HR (95% CI) | n (%) | Median OS, mo (95% CI) | OS probability vs Q0, HR (95% CI) | |
Q0a | 105 (22) | 26.9 (18.6–NE) | – | 94 (20) | 12.4 (9.5–15.0) | – |
Q1 | 107 (22) | NR (29.9–NE) | 0.63 (0.43–0.93)b | 137 (30) | 31.9 (22.1–37.8) | 0.48 (0.35–0.67)b |
Q2 | 64 (13) | NR (26.1–NE) | 0.65 (0.42–1.01)b | 109 (24) | NR (NE) | 0.21 (0.14–0.32)b |
Q3 | 96 (20) | NR (NE) | 0.22 (0.13–0.38)b | 73 (16) | NR (NE) | 0.18 (0.11–0.29)b |
Q4 | 107 (22) | NR (NE) | 0.18 (0.11–0.32)b | 46 (10) | NR (NE) | 0.08 (0.03–0.17)b |
Among Q0 pts, median OS was longer and OS probabilities were notably higher with N+I vs S.
bP < 0.0001 when compared with Q0 in the same arm. CI, confidence interval; HR, hazard ratio; NE, not estimable; NR, not reached.
Conclusions
The relationships between DepOR and OS are distinct for N+I vs S, with a greater percentage of N+I pts having prolonged OS. Similar notable OS benefits in N+I DepOR Q3 and Q4 suggest that a DepOR threshold >50% may be a useful indicator of potential for long-term survival with N+I in aRCC pts. Prospective analyses to determine clinical applications are needed.
Clinical trial identification
NCT02231749.
Editorial acknowledgement
Jen Tyson, PhD, and Lawrence Hargett of Parexel.
Legal entity responsible for the study
Bristol-Myers Squibb.
Funding
Bristol-Myers Squibb and ONO Pharmaceutical Company Limited.
Disclosure
V. Grünwald: Research grant / Funding (institution), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Non-remunerated activity/ies: MSD; Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Novartis; Research grant / Funding (institution), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Non-remunerated activity/ies: BMS; Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck Serono; Travel / Accommodation / Expenses, Non-remunerated activity/ies: Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Lilly; Travel / Accommodation / Expenses, Non-remunerated activity/ies: PharmaMar; Travel / Accommodation / Expenses: Nanobiotix; Travel / Accommodation / Expenses: Janssen; Travel / Accommodation / Expenses, Non-remunerated activity/ies: Eisai; Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Ipsen; Research grant / Funding (institution), Travel / Accommodation / Expenses: Eusa Pharm. T.K. Choueiri: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Cerulean; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Eisai; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Foundation Medicine Inc; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Exelixis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: GlaxoSmithKline; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Peloton; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Prometheus Labs; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Corvus; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: IPSEN; Research grant / Funding (institution): Tracon; Research grant / Funding (institution): Astellas. B.I. Rini: Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): GNE/Roche; Advisory / Consultancy, Research grant / Funding (institution): Peloton; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Aveo; Advisory / Consultancy: Novartis; Advisory / Consultancy: Synthorx; Advisory / Consultancy: Compugen; Advisory / Consultancy: Merck; Advisory / Consultancy: Corvus; Advisory / Consultancy: Exelixis; Shareholder / Stockholder / Stock options: PTC Therapeutics. T. Powles: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Merck; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Ipsen; Research grant / Funding (institution): Exelixis. S. George: Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Research grant / Funding (institution): Novartis; Travel / Accommodation / Expenses: Exelixis; Travel / Accommodation / Expenses: Janssen; Research grant / Funding (institution), Travel / Accommodation / Expenses: Corvus; Travel / Accommodation / Expenses: Genentech; Travel / Accommodation / Expenses: Sanofi/Genzyme; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Research grant / Funding (institution): Acceleron; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Agensys; Research grant / Funding (institution): Eisai; Travel / Accommodation / Expenses: EMD Serono. M. Grimm: Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Bayer HealthCare; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Intuitive Surgical; Travel / Accommodation / Expenses: Sanofi Aventis; Travel / Accommodation / Expenses: Hexal; Travel / Accommodation / Expenses: Apogepha; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Janssen Cilag; Travel / Accommodation / Expenses: Ono Pharma; Travel / Accommodation / Expenses: IPSEN. M.B. McHenry: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. M. Maurer: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. R.J. Motzer: Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (institution): Exelixis; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Incyte; Advisory / Consultancy: Lilly. H.J. Hammers: Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Exelixis; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Armo Biosciences; Advisory / Consultancy: Novartis. N.M. Tannir: Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Nektar Therapeutics; Advisory / Consultancy: Oncorena; Advisory / Consultancy, Research grant / Funding (institution): Exelixis; Advisory / Consultancy: Eisai; Research grant / Funding (institution): Calithera Bioscience; Advisory / Consultancy: Ono Pharmaceutical. L. Albiges: Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Advisory / Consultancy: Ipsen; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract